OVER THE NEXT DECADE BIOQUARTER WILL TRANSITION INTO EDINBURGH’S HEALTH INNOVATION DISTRICT
University of Strathclyde4
are actively exploring
the potential of improving technology for brain repair using several strategies which include stem cells, biomaterials, tissue engineering, immunomodulation, genetic engineering and neurorehabilitation. These ‘lab-on-a-chip technologies’ improve immunomodulation for brain repair with relevance to Alzheimer’s disease and stroke.
Impact on patient care and the future of medicine The advancements made in pharmaceutical research in Scotland have the potential to significantly impact patient care and the future of medicine in several ways: Improved treatment efficacy and safety: New discoveries can lead to the development of more effective and safer medications with fewer side effects, ultimately improving patient outcomes and quality of life. For instance, research conducted at the University of Aberdeen5
on
novel treatments for neurodegenerative diseases like Alzheimer's and Parkinson's aims to provide patients with improved symptom management and potentially slow disease progression.
Driving innovation and collaboration: Scotland's vibrant research environment fosters collaboration and innovation, attracting leading researchers and pharmaceutical companies. This
Personalized medicine revolution: Tailoring treatments to individual patients based on their specific needs can lead to more effective therapies and potentially reduce the burden of treatment-related complications. The Stratified Medicine Scotland initiative, a collaborative effort involving multiple institutions, laid the foundations towards implementing personalized medicine approaches across various disease areas, with a focus on improving patient care and optimizing treatment effectiveness.
Addressing unmet medical needs: Research focused on areas like gene therapy and novel antibiotics has the potential to offer solutions for previously untreatable conditions, improving the lives of millions worldwide. The work of scientists at the University of Edinburgh6
on developing
gene therapies for inherited blood disorders exemplifies this potential, offering hope for individuals currently lacking effective treatment options.
collaborative spirit fuels advancements in the field, as exemplified by the BioQuarter7
in
Edinburgh, a hub for life sciences research that brings together academia, industry, and government to accelerate innovation and drug discovery. Over the next decade BioQuarter will transition into Edinburgh’s Health Innovation District
Looking ahead: A bright future for pharmaceutical research in Scotland The future of pharmaceutical research in Scotland is undeniably bright. With continued investment, collaboration, and a focus on cutting- edge technologies, Scottish researchers are well-positioned to make significant contributions to improving global health and shaping the future of medicine. A new Engineered Genetic Control Systems for Advanced Therapeutics Hub at the University of Edinburgh6
will establish improved
gene therapy techniques for patients with serious conditions. The hub will create new biological tools to improve the effectiveness and safety of gene therapies, testing them in cancers, cardiovascular disease and rare diseases.
“Gene therapies have the potential to revolutionise healthcare by treating or even curing disease. But for them to be effective and safe they need to be delivered to the right place in the body, in the right amount, and for the right length of time. This is where engineering biology comes in. By developing a suite of tools and training scientists for academia and industry, we hope to realise the UK’s potential to be a global leader in engineering biology for healthcare and, ultimately, to improve global health.” Professor Susan Rosser, Chair of Synthetic Biology, School of Biological Sciences and School of Engineering
By harnessing the potential of these advancements, Scotland can continue its legacy of pioneering breakthroughs and ensuring that the benefits of innovative treatments reach patients worldwide.
Sources: 1:
https://www.precisionmedicinescotland.com/ 2:
https://www.dundee.ac.uk/stories/ps44-million-video-edit- genes 3:
https://medicine.st-andrews.ac.uk/igh/slic/ 4:
https://www.strath.ac.uk/research/subjects/pharmacybiomedicals ciences/neuroscienceandmentalhealth/ 5:
https://www.abdn.ac.uk/ims/research/neuroscience-2085.php 6:
https://www.ed.ac.uk/news/2024/game-changing-gene- therapies-focus-of-14m-hub
7:
https://edinburghbioquarter.com/
scottishpharmacist.com 39
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
